These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26824047)

  • 61. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
    Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
    J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention.
    Nusca A; Tuccinardi D; Proscia C; Melfi R; Manfrini S; Nicolucci A; Ceriello A; Pozzilli P; Ussia GP; Grigioni F; Di Sciascio G
    Cardiovasc Diabetol; 2019 Nov; 18(1):147. PubMed ID: 31706305
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
    Raju NC; Eikelboom JW; Hirsh J
    Nat Clin Pract Cardiovasc Med; 2008 Dec; 5(12):766-80. PubMed ID: 18957959
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
    Guimarães PO; Tricoci P
    Expert Opin Pharmacother; 2015; 16(13):1983-95. PubMed ID: 26224244
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel.
    Bonello L; Mancini J; Pansieri M; Maillard L; Rossi P; Collet F; Jouve B; Wittenberg O; Laine M; Michelet P; Bessereau J; Lemesle G; Dignat-George F; Paganelli F; Camoin-Jau L
    J Thromb Haemost; 2012 Oct; 10(10):1999-2005. PubMed ID: 22863374
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.
    Tam CC; Kwok J; Wong A; Yung A; Shea C; Kong SL; Tang WH; Siu D; Chan R; Lee S
    J Int Med Res; 2017 Feb; 45(1):134-146. PubMed ID: 28222641
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
    Clemmensen P; Dridi NP; Holmvang L
    Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans.
    Park KW; Park JJ; Jeon KH; Kang SH; Oh IY; Yang HM; Cho HJ; Lee HY; Kang HJ; Koo BK; Oh BH; Park YB; Kim HS
    Cardiovasc Ther; 2012 Feb; 30(1):5-11. PubMed ID: 21129165
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
    Floyd CN; Passacquale G; Ferro A
    Clin Pharmacokinet; 2012 Jul; 51(7):429-42. PubMed ID: 22568693
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prasugrel or Ticagrelor in ST-Segment-Elevation Myocardial Infarction Patients With Diabetes Mellitus.
    Sardella G; Mancone M; Stio RE; Cavallo E; Di Roma A; Colantonio R; Calcagno S
    Circulation; 2017 Aug; 136(6):602-604. PubMed ID: 28784829
    [No Abstract]   [Full Text] [Related]  

  • 71. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
    Olivier CB; Schnabel K; Weber S; Zhou Q; Bode C; Moser M; Diehl P
    J Thromb Thrombolysis; 2016 Jul; 42(1):84-9. PubMed ID: 26837379
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
    Cattaneo GJ; Podda GM; Cattaneo M
    Recenti Prog Med; 2011 Apr; 102(4):150-5. PubMed ID: 21572491
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The STIB score: a simple clinical test to predict clopidogrel resistance.
    Legrand D; Barbato E; Chenu P; Magne J; Vrolix M; Wijns W; Legrand V;
    Acta Cardiol; 2015 Oct; 70(5):516-21. PubMed ID: 26567810
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Liver Function is Associated With Response to Clopidogrel Therapy in Patients Undergoing Angioplasty and Stenting.
    Gremmel T; Mueller M; Koppensteiner R; Panzer S
    Angiology; 2016 Oct; 67(9):835-9. PubMed ID: 26416820
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PRotective Effect on the coronary microcirculation of patients with DIabetes by Clopidogrel or Ticagrelor (PREDICT): study rationale and design. A randomized multicenter clinical trial using intracoronary multimodal physiology.
    Cerrato E; Quirós A; Echavarría-Pinto M; Mejia-Renteria H; Aldazabal A; Ryan N; Gonzalo N; Jimenez-Quevedo P; Nombela-Franco L; Salinas P; Núñez-Gil IJ; Rumoroso JR; Fernández-Ortiz A; Macaya C; Escaned J
    Cardiovasc Diabetol; 2017 May; 16(1):68. PubMed ID: 28526024
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease.
    Zafar MU; Baber U; Smith DA; Sartori S; Contreras J; Rey-Mendoza J; Linares-Koloffon CA; Escolar G; Mehran R; Fuster V; Badimon JJ
    Thromb Haemost; 2017 Oct; 117(10):1981-1988. PubMed ID: 28837213
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study.
    Pourdjabbar A; Hibbert B; Chong AY; Le May MR; Labinaz M; Simard T; Ramirez FD; Lugomirski P; Maze R; Froeschl M; Glover C; Dick A; Marquis JF; Bernick J; Wells G; So DY;
    Thromb Haemost; 2017 Jan; 117(2):303-310. PubMed ID: 27761582
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of initial clinical presentation on clopidogrel low response.
    Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM; Lemesle G
    Arch Cardiovasc Dis; 2013 Nov; 106(11):593-600. PubMed ID: 24070598
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience.
    Castini D; Persampieri S; Cazzaniga S; Ferrante G; Centola M; Lucreziotti S; Salerno-Uriarte D; Sponzilli C; Carugo S
    Ther Adv Cardiovasc Dis; 2017 Dec; 11(12):323-331. PubMed ID: 29134853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.